Tesamorelin Dosing Protocol: 10 mg Vial — Extended Supply Dosing Guide

Tesamorelin Dosing Protocol: 10 mg Vial — Extended Supply Dosing Guide

Quickstart highlights

Tesamorelin's FDA-approved 2 mg/day protocol demonstrated 15.2% visceral fat reduction at 26 weeks in Phase 3 (Falutz et al., 2010).

  • Concentration: 2 mg/mL (10 mg vial + 5 mL bacteriostatic water).
  • At 2 mg/mL: 2 mg = 100 units (full 1 mL) once daily — the FDA-approved Egrifta SV dose.
  • One 10 mg vial provides exactly 5 daily doses at 2 mg — reconstitute twice weekly.
  • Phase 3 (Falutz et al.): 2 mg/day x 26 weeks reduced visceral fat 15.2% vs. 0.7% placebo.
  • Refrigerate; use within 28 days.

Dosing table

For educational reference only. Your prescribing provider may adjust doses based on your clinical profile and response.

WeekDose (µg)UnitsFrequencyNotes
1-4100050Once daily1 mg — 50 units; 10 mg vial provides 10 doses at this level (10 days)
5-262000100Once daily2 mg — 100 units (FDA-approved dose); 10 mg vial provides 5 daily doses (5 days)

Your free Tesamorelin tracker

  • Dose reminders
  • Injection logging
  • Cycle progress
Add your listing Already have one? Sign in

Reconstitution steps

  1. Draw 5 mL bacteriostatic water in two 2.5 mL draws; inject slowly down the vial wall.
  2. Swirl gently until powder dissolves fully; do not shake.
  3. Final concentration: 2 mg/mL. Label with date; refrigerate at 2–8 °C. Use within 28 days.
  4. One 10 mg vial covers 5 daily doses at 2 mg — plan reconstitution twice weekly at the 2 mg/day maintenance dose.

Supplies needed

12-week plan

  • 12 vials
  • 84 syringes
  • 60 mL bac water
  • 84 alcohol swabs

26-week plan

  • 37 vials
  • 182 syringes
  • 185 mL bac water
  • 182 alcohol swabs
Need clinics? See vetted providers →
Advertisement

Protocol overview & cycle notes

Reduce visceral adipose tissue through twice-weekly reconstitution of tesamorelin 10 mg vials at the 2 mg/day FDA-approved dose, providing 5 days of injections per reconstitution event.

Cycle length: 26 weeks on.

Off-cycle: 8 weeks off; measure IGF-1 and visceral fat surrogate (waist circumference) before resuming.

Storage & handling

Lyophilized: store below 25 °C or refrigerate. Reconstituted at 2 mg/mL: refrigerate 2–8 °C; use within 28 days. At 2 mg/day: one 10 mg vial lasts 5 days — reconstitute approximately twice weekly.

Injection & tracking tips

  • Reconstitute twice weekly at the 2 mg/day dose — one 10 mg vial covers exactly 5 daily injections.
  • Inject at the same time daily (morning preferred) in the abdomen, 2 inches from the navel; rotate within quadrants.
  • Store used vials cap-side down in the refrigerator door; inspect for cloudiness before each draw.

Tracking

Logging helps you and your provider spot patterns and adjust dose or timing.

  • Measure waist circumference weekly as a visceral fat proxy.
  • Track IGF-1 every 8 weeks; target upper-normal for age.
  • Monitor fasting glucose monthly; tesamorelin can increase glucose by 5–10 mg/dL in insulin-resistant patients.
Log your cycle in the calculator →

How this works & references

Tesamorelin's FDA-approved 2 mg/day protocol demonstrated 15.2% visceral fat reduction at 26 weeks in Phase 3 (Falutz et al., 2010). The 10 mg vial offers a modest logistical advantage over 5 mg vials at the 2 mg/day dose: reconstitution every 5 days versus every 2.5 days, roughly halving the number of reconstitution events and associated sterility risks.

Frequently asked questions

How many 10 mg vials do I need for a 26-week protocol at 2 mg/day?
182 total doses at 2 mg = 364 mg total. At 10 mg/vial: 364 ÷ 10 = 36.4 — approximately 37 vials for the full 26-week protocol. Budget accordingly or consider the 20 mg vial for fewer reconstitutions.
Is the 10 mg vial significantly more convenient than the 5 mg vial?
At 2 mg/day: 5 mg vial lasts 2.5 days (reconstitute every 2.5 days = ~2.8 times per week); 10 mg vial lasts 5 days (reconstitute twice per week). The 10 mg vial reduces reconstitution events by approximately 50%, which is meaningful over a 26-week protocol.
Can tesamorelin be used for weight loss in non-HIV patients?
Off-label use for visceral fat reduction in non-HIV patients occurs in practice, but the Phase 3 evidence base is specific to HIV-associated lipodystrophy. The mechanism (visceral fat lipolysis via GH/IGF-1 elevation) is independent of HIV status, suggesting plausible efficacy — but no Phase 3 data in non-HIV populations exists.
Does tesamorelin improve triglycerides as well as visceral fat?
Yes — the Falutz Phase 3 trial showed triglyceride reduction as a secondary endpoint: approximately 50 mg/dL reduction from baseline at 26 weeks in the tesamorelin arm. The mechanism is GH-mediated enhancement of lipoprotein lipase activity and VLDL clearance.
What are the signs of excessive tesamorelin dose?
Signs of supraphysiological GH elevation include: carpal tunnel syndrome (wrist/finger tingling), joint pain (arthralgia), edema (ankle swelling), and elevated fasting glucose. If IGF-1 exceeds 350 ng/mL for age, reduce dose to 1 mg/day and reassess.

Related protocols

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any peptide therapy. Dosing and protocols may vary by formulation and prescriber.

Sign In

Register

Reset Password

Please enter your username or email address, you will receive a link to create a new password via email.